Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. BerGenBio ASA
  6. News
  7. Summary
    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BerGenBio ASA: Increase of share capital, exercise of share options

09/30/2021 | 11:07am EST
Bergen, Norway, 30 September 2021

The Board of Directors in BerGenBio ASA (the "Company") (OSE: BGBIO) have, to
fulfil the Company's obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, resolved to increase the Company's share capital by NOK 13,750 by issuance
of 137,500 new shares. The new shares are subscribed for by option owners who
wishes and are entitled to exercise options in accordance with the Company's
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme, in average NOK 16.01 per share.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,838,525.50 consisting of 88,385,255 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the
expectations expressed or implied in this announcement by such forward-looking
statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about BERGENBIO ASA
11/17BERGENBIO ASA : Share capital increase
AQ
11/16Bergenbio asa - results for the third quarter of 2021
AQ
11/16BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/16BERGENBIO ASA : Results for the third quarter of 2021
AQ
11/09BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
11/09BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced..
PU
11/09BerGenBio ASA Presents Pre-Clinical and Clinical Data on Bemcentinib in STK11-Positive ..
CI
11/09Bergenbio receives fda fast track designation for bemcentinib inástk11-mutated advanced..
AQ
11/09Bergenbio presents pre-clinical and clinical data onábemcentinib in stk11-positive nscl..
AQ
11/04Bergenbio to present updated bemcentinibáaml data atáash 2021 meeting
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -309 M -34,3 M -34,3 M
Net cash 2021 402 M 44,6 M 44,6 M
P/E ratio 2021 -5,17x
Yield 2021 -
Capitalization 1 606 M 178 M 178 M
EV / Sales 2021 -
EV / Sales 2022 6,00x
Nbr of Employees 46
Free-Float 57,5%
Chart BERGENBIO ASA
Duration : Period :
BerGenBio ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BERGENBIO ASA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 18,16 NOK
Average target price 53,67 NOK
Spread / Average Target 196%
EPS Revisions
Managers and Directors
Martin Olin Chief Executive Officer
Rune Skeie Chief Financial Officer
Sveinung Hole Chairman
Alison Messom Director-Clinical Operations
E. Gwyn Thomas Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BERGENBIO ASA-45.99%169
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137